Like in the more familiar story of polio vaccine, the development of the first successful live attenuated vaccine against measles began in the laboratory of John Enders. One of the greatest virologists of the 20th century, Enders pioneered the technique of viral tissue culture, which makes it possible to grow viruses in vitro in cells nourished in laboratory media.1 In 1949, he and his pediatric infectious disease fellows Thomas Weller and Frederick Robbins showed that poliovirus could be cultivated in tissue of nonneuronal origins, a discovery that set the stage for the first successful vaccines against the disease and led to a Nobel Prize in 1954.2 Enders himself was a remarkable character. He never tried to patent his work or share results with the media before peer review. He was consistently generous in sharing his knowledge with potential competitors, and despite his personal wealth he was equally known...
Skip Nav Destination
Article navigation
September 2011
Pediatrics Perspectives|
September 01 2011
The First Measles Vaccine Available to Purchase
Jeffrey P. Baker, MD, PhD
Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina
Address correspondence to Jeffrey P. Baker, MD, PhD, Trent Center for Bioethics, Humanities, and History of Medicine, Box 3040 DUMC, Durham, NC 27710. E-mail: [email protected]
Search for other works by this author on:
Address correspondence to Jeffrey P. Baker, MD, PhD, Trent Center for Bioethics, Humanities, and History of Medicine, Box 3040 DUMC, Durham, NC 27710. E-mail: [email protected]
FINANCIAL DISCLOSURE: The author has indicated he has no financial relationships relevant to this article to disclose.
Pediatrics (2011) 128 (3): 435–437.
Article history
Accepted:
June 21 2011
Citation
Jeffrey P. Baker; The First Measles Vaccine. Pediatrics September 2011; 128 (3): 435–437. 10.1542/peds.2011-1430
Download citation file:
Sign in
Don't already have an account? Register
Purchased this content as a guest? Enter your email address to restore access.
Please enter valid email address.
Pay-Per-View Access
$35.00
Comments